Alternative splicing is a critical mechanism for gene regulation and generating proteomic diversity. It affects human development and is involved in many diseases. Recent studies show that alternative splicing is regulated by an intricate protein-RNA network, with progress made through individual transcript studies and genome-wide approaches. Alternative splicing involves the removal of introns and is catalyzed by the spliceosome, a complex structure involving snRNPs and auxiliary proteins. The decision to include or exclude an exon is influenced by RNA sequence elements and protein regulators, such as SR proteins, which bind to exonic splicing enhancers (ESEs) and mediate interactions. Inhibitors like hnRNP A1 and FOX1/FOX2 can block splice site recognition by sterically blocking snRNPs or by altering mRNA structure. The position of cis-acting elements and their binding proteins can determine splicing outcomes, with some elements acting as repressors or activators depending on their location. RNA secondary structures can also influence splicing by masking splice sites or binding sites for splicing factors. Splicing is also regulated by post-translational modifications, such as phosphorylation, which can alter the activity and localization of splicing factors. Tissue-specific splicing is controlled by differentially expressed splicing regulators and splicing factors, with SR proteins and hnRNPs playing key roles. Alternative splicing is essential for tissue specificity, with many splicing factors showing tissue-specific expression. The regulation of alternative splicing is complex, involving multiple mechanisms, including cis-acting elements, protein interactions, and post-translational modifications. Understanding these mechanisms is crucial for elucidating the molecular basis of alternative splicing and its role in disease.Alternative splicing is a critical mechanism for gene regulation and generating proteomic diversity. It affects human development and is involved in many diseases. Recent studies show that alternative splicing is regulated by an intricate protein-RNA network, with progress made through individual transcript studies and genome-wide approaches. Alternative splicing involves the removal of introns and is catalyzed by the spliceosome, a complex structure involving snRNPs and auxiliary proteins. The decision to include or exclude an exon is influenced by RNA sequence elements and protein regulators, such as SR proteins, which bind to exonic splicing enhancers (ESEs) and mediate interactions. Inhibitors like hnRNP A1 and FOX1/FOX2 can block splice site recognition by sterically blocking snRNPs or by altering mRNA structure. The position of cis-acting elements and their binding proteins can determine splicing outcomes, with some elements acting as repressors or activators depending on their location. RNA secondary structures can also influence splicing by masking splice sites or binding sites for splicing factors. Splicing is also regulated by post-translational modifications, such as phosphorylation, which can alter the activity and localization of splicing factors. Tissue-specific splicing is controlled by differentially expressed splicing regulators and splicing factors, with SR proteins and hnRNPs playing key roles. Alternative splicing is essential for tissue specificity, with many splicing factors showing tissue-specific expression. The regulation of alternative splicing is complex, involving multiple mechanisms, including cis-acting elements, protein interactions, and post-translational modifications. Understanding these mechanisms is crucial for elucidating the molecular basis of alternative splicing and its role in disease.